This study investigated the peripapillary deep-layer circulation using OCTA in consecutive primary open-angle glaucoma (POAG) patients and healthy control subjects who were enrolled in the Investigating Glaucoma Progression Study, which is an ongoing prospective study at the Glaucoma Clinic of Seoul National University Bundang Hospital Glaucoma Clinic. Written informed consent to participate was obtained from all of the subjects. The study protocol was approved by the Institutional Review Board of Seoul National University Bundang Hospital and it followed the tenets of the Declaration of Helsinki.
All of the participants underwent comprehensive ophthalmic examinations that included best-corrected visual acuity (BCVA), Goldmann applanation tonometry, a refraction test, slit-lamp biomicroscopy, gonioscopy, stereo disc photography, red-free fundus photography (EOS D60 digital camera; Canon, Utsunomiyashi, Tochigiken, Japan), central corneal thickness measurement (Orbscan II; Bausch & Lomb Surgical, Rochester, NY, USA), axial length measurement (IOLMaster version 5; Carl Zeiss Meditec, Dublin, CA, USA), corneal curvature measurement (KR-1800; Topcon, Tokyo, Japan), spectral-domain OCT (SD-OCT) scanning of the circumpapillary retinal nerve fiber layer (RNFL) and the optic disc using enhanced depth imaging (EDI) mode (Spectralis; Heidelberg Engineering, Heidelberg, Germany), standard automated perimetry (Humphrey Field Analyzer II 750, 24-2 Swedish interactive threshold algorithm; Carl Zeiss Meditec), and swept-source OCTA (DRI OCT Triton; Topcon). The clinical history was also obtained from all of the participants including demographic characteristics, the presence of cold extremities or migraine, and other systemic diseases. Systolic and diastolic BP were measured at the time of OCTA. Mean arterial pressure (MAP) and mean ocular perfusion pressure (MOPP) were calculated based on the following equations: MAP = diastolic BP + 1/3 (systolic BP–diastolic BP) and MOPP = MAP–IOP at the time of OCTA.
POAG was defined as the presence of an open iridocorneal angle, signs of glaucomatous optic nerve damage (i.e., neuroretinal rim thinning, notching, or an RNFL defect), and a glaucomatous VF defect. A glaucomatous VF defect was defined as a defect conforming with one or more of the following criteria: outside normal limits on a glaucoma hemifield test; three abnormal points with a P < 5% probability of being normal and one abnormal point with a P < 1% by pattern deviation; or a pattern standard deviation of P < 5% confirmed on two consecutive reliable tests (fixation loss rate ≤ 20% and false-positive and false-negative error rates ≤ 25%). Healthy controls had an IOP ≤ 21 mm Hg, no history of increased IOP, an optic disc with a normal appearance, and a normal VF. Healthy control eyes were selected by matching them with POAG eyes in terms of age and axial length. The specific parameter values used to indicate a match were as follows: age within 2 years and axial length within 0.1 mm. Each healthy eye was matched with two POAG eyes (i.e., 2:1 matching). To be included in this study, both POAG and healthy control eyes were required to have a parapapillary γ-zone (see below).
Exclusion criteria included eyes with a BCVA worse than 20/40, a spherical equivalent <−9.0 D or >+3.0 D, a cylinder correction <−3.0 D or >+3.0 D, a history of intraocular surgery with the exception of uneventful cataract surgery or trabeculectomy, or retinal or neurologic diseases. When both eyes were eligible, one eye was randomly selected for inclusion in the study.
Eyes included in the POAG group were required to have a record of untreated IOP, which was measured prior to the initiation of ocular hypotensive treatment or was identified in the referral notes. In patients with an untreated IOP ≤ 21 mm Hg, diurnal variation was measured during office hours (9 AM to 5 PM). In patients undergoing treatment with ocular hypotensive medication at the time of the initial visit, diurnal variation was measured after a 4-week washout period.